Pharmaceutical Technology

FEBRUARY 23, 2023

Our chemists and formulation scientists review the properties of new drug candidates and “work their magic” to develop formulations that improve the exposure profile of the compound. However, the chances of improving the exposure profile of a drug that is highly cleared by formulation modification are limited.

Drug Development 98

Drug Development Compounding Dosage Packaging 98

European Pharmaceutical Review

JULY 14, 2023

However, extensive capital investment and complex infrastructure is necessary for carrying out in-house filling of biologics and small molecules, which can be a challenge for drug developers with limited finances and capacity constraints. The global aseptic fill finish market Which packaging container type has the highest share?

Packaging 88

Packaging Compounding Drug Development 88

Pharmaceutical Technology

MARCH 22, 2023

The demand for injectable drugs is rising. According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. Several drug development trends are driving injectables demand.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

NOVEMBER 22, 2022

The company focuses on so-called ‘undruggable’ targets – those that have defied the efforts of drug developers using conventional treatment approaches.

Packaging 52

Packaging Compounding Drug Development 52

European Pharmaceutical Review

JUNE 24, 2022

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. pocket expenses account for only seven percent of the overall cost of developing drugs.

Compounding 99

Compounding Drug Development Drug Pricing Dosage 99

Pharmaceutical Technology

DECEMBER 9, 2022

Research and development highlights from the research period include the company’s work with Mirati Therapeutics in developing methods to determine torsion rotational energy barriers of the clinical compound, MRTX1719, which is being developed for use as an inhibiter to MTAP-deleted cancers.

Vaccines 52

Vaccines Biosimilars Compounding Packaging 52

Pulses

AUGUST 31, 2023

References Ley D, Parkes D, Walton G. 6-emerging technologies for learning.

Medication Dispensing 78

Medication Dispensing Medication Labelling Packaging Compounding 78